Semaglutide for diabetes mellitus

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Diabetes Mellitus, Type 2, Prediabetic State

Why this status

  1. 7 Jun 2021: Trial registered, NCT04916470
  2. 15 Jun 2021: Trial started, NCT04916470

The trials

NCT04916470: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

State
Completed
Phase
Phase 3
People
617 taking part
Started
15 Jun 2021
Primary completion
11 Oct 2023
Arms
Semaglutide 2.4 mg once weekly (OW)
Results
Posted on the registry
  1. 7 Jun 2021: Trial registered
  2. 15 Jun 2021: Trial started
  3. 11 Oct 2023: Trial completed
  4. 2 Nov 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.